Nivolumab in combinatie met chemo-immuuntherapie voor de behandeling van nieuw gediagnosticeerd primair mediastinaal B-cellymfoom
Een gerandomiseerde fase 3-studie van nivolumab (NSC# 748726) in combinatie met chemo-immunotherapie voor de behandeling van nieuw gediagnosticeerd primair mediastinaal B-cellymfoom
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Studie Overzicht
Toestand
Interventie / Behandeling
- Geneesmiddel: Cyclophosphamide
- Geneesmiddel: Doxorubicin Hydrochloride
- Geneesmiddel: Prednisone
- Biologisch: Rituximab
- Geneesmiddel: Vincristine Sulfate
- Procedure: Echocardiography Test
- Biologisch: Nivolumab
- Procedure: Computed Tomography
- Procedure: Positron Emission Tomography
- Geneesmiddel: Etoposide Phosphate
- Biologisch: Filgrastim
- Procedure: Bone Marrow Aspiration
- Procedure: Bone Marrow Biopsy
- Straling: Radiation Therapy
- Geneesmiddel: Prednisolone
- Biologisch: Pegfilgrastim
- Procedure: Lumbar Puncture
- Procedure: Biospecimen Collection
- Biologisch: Rituximab and Hyaluronidase Human
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To determine if nivolumab + chemo-immunotherapy results in a superior long term progression-free survival (PFS) (events defined as disease progression confirmed by central review or death) when compared with chemo-immunotherapy alone in patients with newly diagnosed primary mediastinal B-cell lymphoma.
SECONDARY OBJECTIVES:
I. To compare the rates of "efficacy-related event-free survival (EFS)" (eEFS) (events defined as progression, change in therapy due to finding that led to concern about efficacy, biopsy + disease after 6 cycles of therapy, or death) between chemo-immunotherapy alone and chemo-immunotherapy + nivolumab in patients with newly diagnosed PMBCL.
II. To compare the rates of "therapy-related EFS" (tEFS) (events defined as relapse/progression, change in therapy for any reason, biopsy + disease after 6 cycles of therapy, secondary malignancy [SMN] or death) between chemo-immunotherapy alone and chemo-immunotherapy + nivolumab in patients with newly diagnosed PMBCL.
III. To compare the rates of overall survival (OS) between chemo-immunotherapy alone and chemo-immunotherapy + nivolumab in patients with newly diagnosed PMBCL.
IV. To establish the rate of a positive positron emission tomography (PET)-computed tomography (CT) (defined as Deauville score 4 or 5) at the completion of 6 cycles of nivolumab + rituximab (R)- cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/dose-adjusted (DA)-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH)-R and R-CHOP/DA-EPOCH-R in patients with newly diagnosed PMBCL and evaluate the prognostic significance of such a finding.
EXPLORATORY OBJECTIVES:
I. To bank radiology images for further studies. II. To bank specimens for future correlative studies. III. Characterize the immune profile of patients treated with nivolumab + chemo-immunotherapy to identify markers predictive of response.
IV. Define the rate of complete response at the completion of initial planned therapy.
OUTLINE: Patients are randomly assigned to backbone therapy or backbone therapy + nivolumab within each of 6 strata. The strata are determined by physician's choice of backbone (DA-EPOCH-R versus [vs.] R-CHOP vs. R-CHOP + RT) and whether or not the patient had 1 prior cycle of therapy.
ARM A (DA-EPOCH-R): Patients receive prednisone or prednisolone orally (PO) once daily (QD) on days 1-5 and rituximab intravenously (IV) or rituximab and hyaluronidase human subcutaneously (SC) over 5 minutes on day 1 or 5. Patients also receive etoposide phosphate, doxorubicin hydrochloride, and vincristine sulfate IV over 96 hours on days 1-4 and cyclophosphamide IV over 30-60 minutes on day 5. Beginning 24-72 hours after completing cyclophosphamide, patients receive filgrastim or pegylated filgrastim SC daily until absolute neutrophil count (ANC) is >= 500/uL after the expected nadir. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) during screening and as clinically indicated and a lumbar puncture (LP) for cerebral spinal fluid (CSF) collection optionally during screening. Patients also undergo computed tomography (CT) or positron emission tomography (PET)/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM B (DA-EPOCH-R + NIVOLUMAB): Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM C (R-CHOP): Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM D (R-CHOP + NIVOLUMAB): Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM E (R-CHOP + RADIOTHERAPY): Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
ARM F (R-CHOP + RADIOTHERAPY + NIVOLUMAB): Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study.
After completion of study treatment, patients are followed up every 3 months for year 1, every 6 months for years 2-3, and annually thereafter.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Australië, 2310
- John Hunter Children's Hospital
-
Westmead, New South Wales, Australië, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australië, 4101
- Queensland Children's Hospital
-
-
Victoria
-
Parkville, Victoria, Australië, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australië, 6009
- Perth Children's Hospital
-
-
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Janeway Child Health Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
London, Ontario, Canada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
-
-
-
Caguas, Puerto Rico, 00726
- HIMA San Pablo Oncologic Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Verenigde Staten, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Verenigde Staten, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Verenigde Staten, 85202
- Banner Children's at Desert
-
Tucson, Arizona, Verenigde Staten, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Costa Mesa, California, Verenigde Staten, 92627
- UC Irvine Health Cancer Center-Newport
-
Downey, California, Verenigde Staten, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Verenigde Staten, 92618
- City of Hope at Irvine Lennar
-
Irvine, California, Verenigde Staten, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Loma Linda, California, Verenigde Staten, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Verenigde Staten, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Verenigde Staten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Verenigde Staten, 90027
- Children's Hospital Los Angeles
-
Los Angeles, California, Verenigde Staten, 90095
- Mattel Children's Hospital UCLA
-
Madera, California, Verenigde Staten, 93636
- Valley Children's Hospital
-
Oakland, California, Verenigde Staten, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Verenigde Staten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Verenigde Staten, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Verenigde Staten, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Verenigde Staten, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Verenigde Staten, 92123
- Rady Children's Hospital - San Diego
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06106
- Connecticut Children's Medical Center
-
-
Delaware
-
Wilmington, Delaware, Verenigde Staten, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Verenigde Staten, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Verenigde Staten, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Verenigde Staten, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Verenigde Staten, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Verenigde Staten, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, Verenigde Staten, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Verenigde Staten, 32806
- Arnold Palmer Hospital for Children
-
St. Petersburg, Florida, Verenigde Staten, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Verenigde Staten, 33606
- Tampa General Hospital
-
Tampa, Florida, Verenigde Staten, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Verenigde Staten, 30342
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Verenigde Staten, 30308
- Emory Proton Therapy Center
-
Atlanta, Georgia, Verenigde Staten, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Savannah, Georgia, Verenigde Staten, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Aurora, Illinois, Verenigde Staten, 60504
- Rush-Copley Medical Center
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Lurie Children's Hospital-Chicago
-
Danville, Illinois, Verenigde Staten, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Verenigde Staten, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Verenigde Staten, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Verenigde Staten, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Verenigde Staten, 60134
- Northwestern Medicine Cancer Center Delnor
-
Lake Forest, Illinois, Verenigde Staten, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Verenigde Staten, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Verenigde Staten, 60153
- Loyola University Medical Center
-
O'Fallon, Illinois, Verenigde Staten, 62269
- HSHS Saint Elizabeth's Hospital
-
Oak Lawn, Illinois, Verenigde Staten, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Verenigde Staten, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Verenigde Staten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Verenigde Staten, 62702
- Springfield Clinic
-
Springfield, Illinois, Verenigde Staten, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Verenigde Staten, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Verenigde Staten, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Riley Hospital for Children
-
Richmond, Indiana, Verenigde Staten, 47374
- Reid Health
-
-
Iowa
-
Ankeny, Iowa, Verenigde Staten, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Verenigde Staten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Verenigde Staten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Verenigde Staten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Sioux City, Iowa, Verenigde Staten, 51101
- Siouxland Regional Cancer Center
-
Waukee, Iowa, Verenigde Staten, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kansas
-
Wichita, Kansas, Verenigde Staten, 67214
- Wesley Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Verenigde Staten, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Verenigde Staten, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Verenigde Staten, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Verenigde Staten, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Verenigde Staten, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Verenigde Staten, 21204
- Greater Baltimore Medical Center
-
Baltimore, Maryland, Verenigde Staten, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Verenigde Staten, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Verenigde Staten, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Verenigde Staten, 48201
- Children's Hospital of Michigan
-
East Lansing, Michigan, Verenigde Staten, 48823
- Michigan State University
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Verenigde Staten, 49007
- Bronson Methodist Hospital
-
Niles, Michigan, Verenigde Staten, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Corewell Health Children's
-
-
Minnesota
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Verenigde Staten, 55433
- Mercy Hospital
-
Edina, Minnesota, Verenigde Staten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Verenigde Staten, 55432
- Unity Hospital
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Verenigde Staten, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Abbott-Northwestern Hospital
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- United Hospital
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Chesterfield, Missouri, Verenigde Staten, 63017
- Saint Luke's Hospital
-
City of Saint Peters, Missouri, Verenigde Staten, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Verenigde Staten, 63141
- Siteman Cancer Center at West County Hospital
-
Kansas City, Missouri, Verenigde Staten, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Verenigde Staten, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Verenigde Staten, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Verenigde Staten, 63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Verenigde Staten, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Reno, Nevada, Verenigde Staten, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Verenigde Staten, 07920
- Memorial Sloan Kettering Basking Ridge
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Hackensack University Medical Center
-
Middletown, New Jersey, Verenigde Staten, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Verenigde Staten, 07645
- Memorial Sloan Kettering Bergen
-
Morristown, New Jersey, Verenigde Staten, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Paterson, New Jersey, Verenigde Staten, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- Presbyterian Hospital
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Albany Medical Center
-
Buffalo, New York, Verenigde Staten, 14263
- Roswell Park Cancer Institute
-
Commack, New York, Verenigde Staten, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Verenigde Staten, 10604
- Memorial Sloan Kettering Westchester
-
New Hyde Park, New York, Verenigde Staten, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Verenigde Staten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Verenigde Staten, 10065
- NYP/Weill Cornell Medical Center
-
Rochester, New York, Verenigde Staten, 14642
- University of Rochester
-
Stony Brook, New York, Verenigde Staten, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Verenigde Staten, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Verenigde Staten, 10467
- Montefiore Medical Center - Moses Campus
-
Uniondale, New York, Verenigde Staten, 11553
- Memorial Sloan Kettering Nassau
-
Valhalla, New York, Verenigde Staten, 10595
- New York Medical College
-
Webster, New York, Verenigde Staten, 14580
- Wilmot Cancer Institute at Webster
-
-
North Carolina
-
Asheville, North Carolina, Verenigde Staten, 28801
- Mission Hospital
-
Asheville, North Carolina, Verenigde Staten, 28803
- AdventHealth Infusion Center Asheville
-
Charlotte, North Carolina, Verenigde Staten, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Verenigde Staten, 27834
- East Carolina University
-
Hendersonville, North Carolina, Verenigde Staten, 28792
- AdventHealth Hendersonville
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Verenigde Staten, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Verenigde Staten, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Verenigde Staten, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Verenigde Staten, 45404
- Dayton Children's Hospital
-
Dayton, Ohio, Verenigde Staten, 45415
- Dayton Physician LLC - Englewood
-
Kettering, Ohio, Verenigde Staten, 45429
- Kettering Medical Center
-
Kettering, Ohio, Verenigde Staten, 45409
- Greater Dayton Cancer Center
-
Toledo, Ohio, Verenigde Staten, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Verenigde Staten, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Verenigde Staten, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Verenigde Staten, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Verenigde Staten, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Verenigde Staten, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Verenigde Staten, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Verenigde Staten, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Verenigde Staten, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Verenigde Staten, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Verenigde Staten, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Verenigde Staten, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Amarillo, Texas, Verenigde Staten, 79106
- Texas Tech University Health Sciences Center-Amarillo
-
Austin, Texas, Verenigde Staten, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Verenigde Staten, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Verenigde Staten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Verenigde Staten, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Verenigde Staten, 79905
- El Paso Children's Hospital
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Verenigde Staten, 77030
- Houston Methodist Hospital
-
Houston, Texas, Verenigde Staten, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Verenigde Staten, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Verenigde Staten, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Verenigde Staten, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Verenigde Staten, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Verenigde Staten, 78229
- Methodist Children's Hospital of South Texas
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84113
- Primary Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Verenigde Staten, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Verenigde Staten, 23507
- Children's Hospital of The King's Daughters
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Verenigde Staten, 24014
- Carilion Children's
-
-
Washington
-
Renton, Washington, Verenigde Staten, 98055
- Valley Medical Center
-
Seattle, Washington, Verenigde Staten, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Verenigde Staten, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Verenigde Staten, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Verenigde Staten, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Charleston, West Virginia, Verenigde Staten, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Marshfield Medical Center-Marshfield
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Age >= 2 years
-
Patient must have histologically confirmed primary mediastinal B-cell lymphoma (PMBCL) as defined by World Health Organization (WHO) criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 or ECOG performance status of 3 if poor performance is related to lymphoma
- Children's Oncology Group (COG) Institutions: Use Karnofsky for patients >= 17 and < 18 years of age and Lansky for patients < 17 years of age
-
Adults (age 18 or older): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight
-
Pediatric Patients (age < 18 years): The following must have been obtained within 14 days prior to registration:
-
Measured or calculated (based on institutional standard) creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2, or
-
Serum creatinine =< 1.5 x institutional upper limit of normal (IULN), or a serum creatinine based on age/sex as follows:
- Age : 2 to < 6 year; Maximum serum creatinine (mg/dL): 0.8 (male; 0.8 (female)
- Age : 6 to < 10 years; Maximum serum creatinine (mg/dL): 1 (male); 1 (female)
- Age : 10 to < 13 years; Maximum serum creatinine (mg/dL): 1.2 (male); 1.2 (female)
- Age : 13 to < 16 years; Maximum serum creatinine (mg/dL): 1.5 (male); 1.4 (female)
- Age : >= 16 years to < 18 years; Maximum serum creatinine (mg/dL): 1.7 (male); 1.4 (female)
-
-
Patients with abnormal liver function will be eligible to enroll if the lab abnormality is thought to be due to the lymphoma or Gilbert's syndrome
-
Age >= 18 years: Ejection fraction of >= 50% by echocardiogram
-
Age < 18 years: Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Administration of prior anti-cancer therapy except as outlined below:
- A short course (=< 2 weeks) of corticosteroids for the relief of lymphoma-related symptoms
- A single course of COP (cyclophosphamide, vincristine, and prednisone)
- One cycle of chemo-immunotherapy including R-CHOP, DA-EPOCH-R, a pediatric mature B-cell non-Hodgkin lymphoma (B-NHL) induction therapy (such as ANHL1131), or intrathecal chemotherapy that has not started more than 21 days prior to enrollment
-
Active ischemic heart disease or heart failure
-
Active uncontrolled infection
-
Central nervous system (CNS) involvement of lymphoma
-
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this trial
-
Active autoimmune disease that has required systemic treatment (such as disease modifying agents, corticosteroids, or immunosuppressive agents) in the past 2 years. Replacement therapy such as thyroxine, insulin or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment
-
In patients < 18 years of age hepatitis B serologies consistent with past or current infections
-
Patients with severe hepatic impairment (Child-Pugh class C or serum total bilirubin > 5.0 mg/dL) unless thought to be due to lymphoma or Gilbert's syndrome
-
Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
-
Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method (failure rate of < 1% per year when used consistently and correctly) for the duration of their study participation
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last dose of rituximab
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm A (DA-EPOCH-R)
See Detailed Description |
Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo ECHO
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Given IV
Andere namen:
Given SC
Andere namen:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Andere namen:
Given PO
Andere namen:
Given SC
Andere namen:
Undergo LP
Andere namen:
Undergo blood and CSF sample collection
Andere namen:
Given SC
Andere namen:
|
|
Experimenteel: Arm B (DA-EPOCH-R, nivolumab)
Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO and LP for CSF collection during screening. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo ECHO
Andere namen:
Given IV
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Given IV
Andere namen:
Given SC
Andere namen:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Andere namen:
Given PO
Andere namen:
Given SC
Andere namen:
Undergo LP
Andere namen:
Undergo blood and CSF sample collection
Andere namen:
Given SC
Andere namen:
|
|
Actieve vergelijker: Arm C (R-CHOP)
Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo ECHO
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Andere namen:
Given PO
Andere namen:
Undergo LP
Andere namen:
Undergo blood and CSF sample collection
Andere namen:
Given SC
Andere namen:
|
|
Experimenteel: Arm D (R-CHOP, nivolumab)
Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo ECHO
Andere namen:
Given IV
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Andere namen:
Given PO
Andere namen:
Undergo LP
Andere namen:
Undergo blood and CSF sample collection
Andere namen:
Given SC
Andere namen:
|
|
Actieve vergelijker: Arm E (R-CHOP, radiation therapy)
Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given IV
Andere namen:
Undergo ECHO
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Andere namen:
Undergo radiation therapy
Andere namen:
Given PO
Andere namen:
Undergo LP
Andere namen:
Undergo blood and CSF sample collection
Andere namen:
Given SC
Andere namen:
|
|
Experimenteel: Arm F (R-CHOP, nivolumab, radiation therapy)
Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions. Patients undergo ECHO during screening and as clinically indicated and LP for CSF collection optionally during screening. Patients also undergo CT or PET/CT throughout the trial. Additionally, patients undergo bone marrow biopsy and aspiration optionally during screening and as clinically indicated on study. Patients undergo blood sample collection on study. |
Given IV
Andere namen:
Given IV
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Undergo ECHO
Andere namen:
Given IV
Andere namen:
Undergo CT or PET/CT
Andere namen:
Undergo PET/CT
Andere namen:
Undergo bone marrow biopsy and aspiration Undergo bone marrow biopsy and aspiration
Andere namen:
Undergo radiation therapy
Andere namen:
Given PO
Andere namen:
Undergo LP
Andere namen:
Undergo blood and CSF sample collection
Andere namen:
Given SC
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS)
Tijdsspanne: From enrollment on the study to first occurrence of relapse/progression or death, assessed up to 7 years
|
The primary analysis will be a one-sided Log-rank test stratified by choice of backbone and radiation therapy and whether the patient had a cycle of therapy prior to enrolling. |
From enrollment on the study to first occurrence of relapse/progression or death, assessed up to 7 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Efficacy-related event-free survival
Tijdsspanne: Up to 7 years
|
Will be analyzed using a one-sided stratified Log-rank test at alpha = 0.05 or 0.025, as appropriate, with events defined as progression, change in therapy due to a finding that led to concern about efficacy, biopsy + disease after 6 cycles of therapy, and death. |
Up to 7 years
|
|
Therapy-related event-free survival
Tijdsspanne: Up to 7 years
|
Will be analyzed using a one-sided stratified Log-rank test at alpha = 0.05 or 0.025, as appropriate, with events defined as progression, change in therapy due to a finding that led to concern about efficacy, biopsy + disease after 6 cycles of therapy, and death. |
Up to 7 years
|
|
Overall survival
Tijdsspanne: Up to 7 years
|
Will be analyzed using a one-sided stratified Log-rank test at alpha = 0.05 or 0.025, as appropriate, with events defined as only death. |
Up to 7 years
|
|
Proportion of positive positron emission tomography (PET) scans
Tijdsspanne: Up to 6 cycle (1 cycle = 21 days)
|
Will be analyzed descriptively with a point estimate and Clopper-Pearson 95% confidence interval in the trial overall and in each treatment arm separately. The prognostic significance of positive PET after 6 cycles of therapy will be evaluated using a Cox proportional hazards regression on PFS with PET result (positive versus [vs.] negative), choice of backbone (rituximab [R]-cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] + radiation therapy [RT] regardless of end-of-therapy imaging vs. R-CHOP without RT unless biopsy positive at end-of-therapy vs. dose-adjusted [DA]-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin [EPOCH]-R without RT unless biopsy positive at end of therapy), and assignment to nivolumab (yes vs. no) as covariates. |
Up to 6 cycle (1 cycle = 21 days)
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Immune profile of patients treated with nivolumab + chemo-immunotherapy
Tijdsspanne: Up to 7 years
|
Analysis will be by paired t-test (for pre- vs. post-treatment measurements) or two-sample equal-variance t-test (for comparisons of nivolumab vs. non-nivolumab or responders [complete response/partial response] vs. non-responders [stable disease/progressive disease]). |
Up to 7 years
|
|
Complete response rate
Tijdsspanne: At the completion of initial planned therapy
|
Will be described using point estimates and Clopper-Pearson 95% confidence intervals for the complete response rate overall and in each treatment arm separately. |
At the completion of initial planned therapy
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Lisa G Roth, Children's Oncology Group
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Peptiden
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Onderzoekstechnieken
- Therapeutica
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Buren
- Chirurgische procedures, operatief
- Cytologische technieken
- Cytodiagnose
- Koolwaterstoffen
- Koolwaterstoffen, cyclisch
- Biologische factoren
- Koolhydraten
- Fysieke fenomeen
- Alkaloïden
- Polycyclische aromatische koolwaterstoffen
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Glycosiden
- Glycoside hydrolasen
- Hydrolasen
- Enzymen
- Enzymen en co -enzymen
- Polysacharide-lyasen
- Koolstofoxygen lyasen
- Lyasen
- Indolen
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Zwangerschap
- Zwangere
- Steroïden
- Verbindingen met gefuseerde ring
- Diagnostische technieken, chirurgisch
- Chemie -technieken, analytisch
- Spectrumanalyse
- Fosforamide mosterd
- Stikstofmosterdverbindingen
- Mosterdverbindingen
- Koolwaterstoffen, gehalogeneerd
- Fosforamides
- Organofosforverbindingen
- Intercellulaire signaalpeptiden en eiwitten
- Zwangerschap
- Zwangerschap
- Vinca -alkaloïden
- Secologanin tryptamine alkaloïden
- Indol alkaloïden
- Indolizidines
- Indolizines
- Antracyclines
- Naftacenes
- Aminoglycosides
- Glycoproteïnen
- Glycoconjugaten
- Antilichamen, monoklonaal, van murine afgeleid
- Daunorubicine
- Diagnostische technieken, neurologisch
- Kolonie-stimulerende factoren
- Hematopoietische celgroeifactoren
- Cytokines
- Nivolumab
- Rituximab
- Prednison
- Prednisolon
- Cyclofosfamide
- Doxorubicine
- Vincristine
- Methylprednisolon
- Radiotherapie
- Hyaluronoglucosaminidase
- Bestraling
- Biopsie
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- Spinale punctie
- CT-P10
- Granulocyt kolonie-stimulerende factor
- Filgrastim
- deltacorteen
- prednylidene
- pegfilgrastim
- etoposide fosfaat
- gepegyleerde granulocyt kolonie-stimulerende factor
Andere studie-ID-nummers
- NCI-2021-01071
- U10CA180886 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2021-01071 (Register-ID: CTRP (Clinical Trial Reporting Program))
- ANHL1931 (Andere identificatie: CTEP)
- ANHL1931 (Andere identificatie: Children's Oncology Group)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .